GlassScriptPhysician profile
Yi-Chun Chou
NPI 1952535890
$4,150.91
in general payments reported to CMS, 2019-2025
15 companies · $1,722 in 2025
The $1,722 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.06 · 2021: $42.67 · 2022: $1,087 · 2023: $886 · 2024: $384 · 2025: $1,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,992.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,339.62 | 2021-2025 | Rinvoq, Humira, Skyrizi |
| Pfizer INC. | $640.42 | 2022-2025 | |
| Glaxosmithkline, LLC. | $535.82 | 2022-2025 | Benlysta |
| Amgen INC. | $477.08 | 2019-2025 | Tavneos, Krystexxa, Otezla |
| Novartis Pharmaceuticals Corporation | $264.46 | 2022-2025 | |
| Ucb, INC. | $232.82 | 2022-2025 | Bimzelx |
| Janssen Biotech, INC. | $155.60 | 2022-2025 | Simponi Aria, Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.91 | 2023-2025 | Ofev, Cyltezo, Jascayd |
| Aurinia Pharma U.S., INC. | $80.14 | 2021-2025 | Lupkynis |
| Genzyme Corporation | $75.80 | 2019-2025 | |
| Horizon Therapeutics Plc | $72.53 | 2022-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $72.25 | 2025 | Saphnelo |
| Genentech USA, INC. | $52.04 | 2025 | Gazyva |
| Kiniksa Pharmaceuticals, LTD. | $35.79 | 2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $15.63 | 2025 | Orencia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi-Chun Chou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.